ArticleFrontiers in endocrinology2026
Estimated small dense low-density lipoprotein cholesterol and hyperuricemia in diabetic patients.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Small dense low-density lipoprotein cholesterol (sdLDL-C) is a key driver of atherosclerotic cardiovascular disease risk. This study aims to investigate the relationship between estimated sdLDL-C (E-sdLDL-C) and hyperuricemia in diabetic populations. Methods: This study analyzed 3572 diabetic participants from the NHANES dataset and an independent validation cohort of 248 Chinese subjects from the Affiliated Wujin Hospital of Jiangsu University. E-sdLDL-C was derived from basic lipid profile parameters. Hyperuricemia was determined by serum uric acid ≥420 μmol/L for men and ≥360 μmol/L for women. The relationship between E-sdLDL-C and hyperuricemia was examined using logistic regression, with restricted cubic splines applied to explore non-linear associations. Results: Diabetic patients with hyperuricemia had significantly higher E-sdLDL-C levels (P<0.001). Each standard deviation increase in E-sdLDL-C was associated with 39% higher odds of hyperuricemia (OR = 1.39, 95% CI: 1.28-1.51, P<0.001). Quartile analysis showed a dose-response relationship, with progressively higher odds ratios across increasing quartiles of E-sdLDL-C. Restricted cubic spline modeling identified a non-linear relationship, with an inflection point at 25.83 μmol/L. The robustness of these associations was confirmed through external validation in an independent Chinese diabetic cohort. Conclusion: E-sdLDL-C might serve as a practical biomarker for identifying diabetic patients at increased hyperuricemia risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.